Icon Plc (ICLR) 60.01 $ICLR
ICON to Acquire MediMedia Pharma Solutions
Business Wire - Mon Feb 02, 5:00AM CST
ICON plc (NASDAQ:ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced it has agreed, subject to certain customary closing conditions, to acquire MediMedia Pharma Solutions for a cash consideration of $120 million. MediMedia Pharma Solutions is division of MediMedia USA and is owned by Vestar Capital Partners.
ICLR: 60.01 (+0.38)
Icon, A Leader In Its Industry, Builds A Base
at Investor's Business Daily - Tue Jan 27, 5:12PM CST
New drugs require clinical trials and those trials increasingly have taken place on an international stage. Many top drug developers outsource an increasing share of trials to companies like Icon (ICLR). Based in Dublin, Icon is one of the top five...
PRXL: 62.91 (-0.18), Q: 63.31 (+0.06), LH: 116.90 (+0.06), ICLR: 60.01 (+0.38), CVD: 107.08 (+0.05)
Biotech Drug Trials Firm Icon Tests New Buy Point
at Investor's Business Daily - Fri Jan 23, 5:34PM CST
Medical stocks have done well recently and Icon (ICLR) may ride that wave to a new breakout. The Ireland-based firm provides clinical research services to pharmaceutical, biotech and medical device companies, helping them bring their products to...
ICLR: 60.01 (+0.38)
5 Top Stocks to Own If Europe's Economy Recovers
Todd Campbell, The Motley Fool - Motley Fool - Thu Jan 22, 3:02PM CST
Source: Ryanair The European Central Bank is pulling a page out of the United States' playbook and launching an aggressive bond buyback program that it hopes will spark an economic recovery similar to what America has enjoyed. Since the U.S....
F: 16.30 (-0.06), RYAAY: 61.46 (-2.33), LUX: 58.79 (-1.11), ICLR: 60.01 (+0.38), IHG: 40.34 (-1.03)
3 High-Flying Health Care Stock IPOs To Watch In 2015
at Investor's Business Daily - Wed Jan 21, 4:09PM CST
Judging by the recent price action of three health care names in today's IPO Leaders screen, the market is optimistic about future growth prospects. When an IPO prices below its proposed range, it's usually because of soft demand. But that wasn't the...
ALDR: 26.06 (+0.18), PRXL: 62.91 (-0.18), ILMN: 198.54 (+1.81), AGIO: 118.55 (+0.11), PRAH: 27.19 (+0.31), BMY: 60.04 (+0.56), ICLR: 60.01 (+0.38)
11 Best Mid-Cap Health Care Stocks Worth Targeting for 2015
at The Street - Fri Jan 02, 1:43PM CST
Which mid-cap health care companies should you target for the best returns? Click through to see which stocks are top-rated.
ACHC: 63.20 (-0.45), SIRO: 91.06 (+0.18), WST: 51.35 (+0.57), USPH: 41.08 (+0.07), ATRI: 332.77 (-2.85), STE: 65.50 (-0.35), GB: 50.86 (+0.20), TFX: 112.07 (+0.47), ICLR: 60.01 (+0.38), CMN: 44.28 (+1.09), UTMD: 58.02 (-0.40)
Healthways-TAL to Improve Well-Being Solutions in Australia - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 5:25PM CST
Healthways Inc. (HWAY) recently entered into a partnership with Australia's specialty life insurer TAL to jointly provide improvement solutions for the latter's members.
EVHC: 36.20 (-0.09), HWAY: 21.32 (+0.01), CRL: 73.61 (-0.33), ICLR: 60.01 (+0.38)
Air Methods: A Strong Sell on Weak Q3 & Estimate Revision - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 12:30PM CST
On Dec 17, 2014, Zacks Investment Research downgraded medical services provider Air Methods Corp (AIRM) to a Zacks Rank #5 (Strong Sell).
AIRM: 45.33 (+0.24), EVHC: 36.20 (-0.09), HQY: 20.02 (+0.04), ICLR: 60.01 (+0.38)
ICON (ICLR) Now a Strong Buy: Should It Be in Your Portfolio? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 5:00PM CST
ICON has been witnessing rising earnings estimates on the back of a new FDA project and an increased guidance for fiscal 2014.
EVHC: 36.20 (-0.09), HQY: 20.02 (+0.04), CRL: 73.61 (-0.33), ICLR: 60.01 (+0.38)
Cancer Genetics (CGIX) Looks Good: Stock Rises 8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 8:25AM CST
Cancer Genetics (CGIX) was a big mover last session, with shares rising just over 8% on the day.
Q: 63.31 (+0.06), CRL: 73.61 (-0.33), ICLR: 60.01 (+0.38), CGIX: 7.07 (unch)
BioTelemetry (BEAT) Catches Eye: Stock Jumps 5.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 28, 7:30AM CST
BioTelemetry, Inc. (BEAT) was a big mover last session, as the company saw its shares rise roughly 6% on the day.
EVHC: 36.20 (-0.09), BEAT: 10.36 (+0.20), CRL: 73.61 (-0.33), ICLR: 60.01 (+0.38)
Will Higher Expenses Hurt Intrexon (XON) Earnings in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 9:50AM CST
Intrexon Corporation (XON) is set to report third-quarter 2014 results on Nov 13.
MNK: 115.01 (+2.51), BEAT: 10.36 (+0.20), XON: 39.30 (+1.05), ICLR: 60.01 (+0.38)
Intrexon (XON) Looks Good: Stock Moves 11% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 8:46AM CST
Intrexon (XON) was a big mover last session, with shares rising almost 11% on the day.
BEAT: 10.36 (+0.20), XON: 39.30 (+1.05), CRL: 73.61 (-0.33), ICLR: 60.01 (+0.38)
Regulatory Affairs Outsourcing Market - Global Industry Analysis 2014 - 2020
M2 - Tue Nov 11, 9:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/8t6h79/regulatory) has announced the addition of the "Regulatory Affairs Outsourcing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020" report to their offering. The global regulatory affairs outsourcing market is segmented by services into regulatory affairs; clinical trial applications and product registrations; regulatory writing and publishing; regulatory consulting and legal representation; and others (post approval maintenance, reimbursement consulting etc.). Regulatory writing and publishing services accounted for the largest share of more than 40% of the overall regulatory affairs outsourcing market in 2013 and is expected to maintain its lead during the forecast period through 2014 to 2020. Factors that have contributed towards the large market size of the regulatory writing and publishing services are increasing need for user/reviewer friendly and complete drug application submissions, and sound knowledge for drug development services. Additionally, a well-written clinical study report (CSR) can help in adding a lot of value in the final production of clinical trial documentation, thereby complying with stringent regulatory requirements of the drug development process. The regulatory consulting and legal representation services segment is also estimated to grow at an approximate CAGR of above 14%. The major driving factors for the rapid growth of this segment are growing demand of drug manufacturing companies for product safety and efficacy evaluations. Furthermore, the need of various pharmaceutical companies to minimize business impacts such as product recalls and loss of sales, and ensure global environmental compliance would also propel the growth of the regulatory consulting and legal representation services segment. Currently, the regulatory affairs outsourcing market is fragmented due to the involvement of several established and emerging contract research organizations. Some of the major players operating in the global regulatory affairs outsourcing market are Charles River Laboratories International, Inc., Covance Group Ltd., Parexel International Corporation, WuXi AppTec, Quintiles Transnational Holdings, Inc., Medpace, Inc., Promedica International, Clinilabs, Inc., Accell Clinical Research, LLC, Criterium, Inc., ICON plc and Pharmaceutical Product Development. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Regulatory Affairs Outsourcing Market Overview Chapter 4 Global Regulatory Affairs Outsourcing Market, by Services Chapter 5 Global Regulatory Affairs Outsourcing Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles - Accell Clinical Research, LLC - Charles River Laboratories International, Inc. - Clinilabs, Inc. - Covance, Inc. - Criterium, Inc. - ICON plc - Medpace, Inc. - PAREXEL International Corporation - PRA International, Inc. - Pharmaceutical Product Development, LLC - Promedica International - Quintiles Transnational Corporation - WuXi AppTec For more information visit http://www.researchandmarkets.com/research/8t6h79/regulatory
PRXL: 62.91 (-0.18), CRL: 73.61 (-0.33), ICLR: 60.01 (+0.38), CVD: 107.08 (+0.05)
Should You Get Rid of Air Methods (AIRM) Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 7:42AM CST
Air Methods has witnessed a significant price decline in the past four weeks and negative earnings estimate revisions for the current quarter and the current year, making it time for investors to sell it off
AIRM: 45.33 (+0.24), Q: 63.31 (+0.06), BEAT: 10.36 (+0.20), ICLR: 60.01 (+0.38)
Air Methods (AIRM) Crumbles: Stock Falls by 7.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:39AM CST
Shares of Air Methods (AIRM) fell by nearly 8% on the day. This continues the recent trend for AIRM, as the stock is now down over 23% since Oct 10. This suggests there may be more trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent slump will continue.
BGMD: 0.88 (unch), AIRM: 45.33 (+0.24), BEAT: 10.36 (+0.20), ICLR: 60.01 (+0.38)
MedAssets Beats on Q3 Earnings, Revenues; Both Rise Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 9:55AM CST
MedAssets, Inc. (MDAS) reported adjusted earnings per share (EPS) of 29 cents in the third quarter of 2014, beating the Zacks Consensus Estimate by couple of cents.
BGMD: 0.88 (unch), BEAT: 10.36 (+0.20), MDAS: 19.81 (+0.18), ICLR: 60.01 (+0.38)
PAREXEL International Beats Q1 Earnings, Misses Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 9:48AM CST
PAREXEL International (PRXL) reported adjusted earnings per share of 65 cents in the first quarter of fiscal 2015, which beat both the Zacks Consensus Estimate of 58 cents and the year-ago earnings of 45 cents.
BGMD: 0.88 (unch), PRXL: 62.91 (-0.18), BEAT: 10.36 (+0.20), ICLR: 60.01 (+0.38)
ICON Selected by the FDA to Develop New Patient-Reported Outcome Measure for Hospital-Acquired Bacterial Pneumonia Trials
Business Wire - Thu Nov 06, 5:11AM CST
ICON plc, (NASDAQ: ICLR) a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been awarded a project by the US Food & Drug Administration (FDA) to develop an industry-standard Patient Reported Outcome (PRO) measure that can be used in anti-bacterial drug development trials for hospital-acquired bacterial pneumonia (HABP).
ICLR: 60.01 (+0.38)
Covance to be Acquired by LabCorp, Shares Surge 25.9% - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 4:15PM CST
Drug-development company Covance Inc.'s (CVD) share price jumped 25.9% to close at $110.57 yesterday
BEAT: 10.36 (+0.20), LH: 116.90 (+0.06), ICLR: 60.01 (+0.38), CVD: 107.08 (+0.05)
ICON to Acquire MediMedia Pharma Solutions
Business Wire - Mon Feb 02, 5:00AM CST
ICON plc (NASDAQ:ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced it has agreed, subject to certain customary closing conditions, to acquire MediMedia Pharma Solutions for a cash consideration of $120 million. MediMedia Pharma Solutions is division of MediMedia USA and is owned by Vestar Capital Partners.
ICLR: 60.01 (+0.38)
Icon, A Leader In Its Industry, Builds A Base
at Investor's Business Daily - Tue Jan 27, 5:12PM CST
New drugs require clinical trials and those trials increasingly have taken place on an international stage. Many top drug developers outsource an increasing share of trials to companies like Icon (ICLR). Based in Dublin, Icon is one of the top five...
PRXL: 62.91 (-0.18), Q: 63.31 (+0.06), LH: 116.90 (+0.06), ICLR: 60.01 (+0.38), CVD: 107.08 (+0.05)
Biotech Drug Trials Firm Icon Tests New Buy Point
at Investor's Business Daily - Fri Jan 23, 5:34PM CST
Medical stocks have done well recently and Icon (ICLR) may ride that wave to a new breakout. The Ireland-based firm provides clinical research services to pharmaceutical, biotech and medical device companies, helping them bring their products to...
ICLR: 60.01 (+0.38)
5 Top Stocks to Own If Europe's Economy Recovers
Todd Campbell, The Motley Fool - Motley Fool - Thu Jan 22, 3:02PM CST
Source: Ryanair The European Central Bank is pulling a page out of the United States' playbook and launching an aggressive bond buyback program that it hopes will spark an economic recovery similar to what America has enjoyed. Since the U.S....
F: 16.30 (-0.06), RYAAY: 61.46 (-2.33), LUX: 58.79 (-1.11), ICLR: 60.01 (+0.38), IHG: 40.34 (-1.03)
3 High-Flying Health Care Stock IPOs To Watch In 2015
at Investor's Business Daily - Wed Jan 21, 4:09PM CST
Judging by the recent price action of three health care names in today's IPO Leaders screen, the market is optimistic about future growth prospects. When an IPO prices below its proposed range, it's usually because of soft demand. But that wasn't the...
ALDR: 26.06 (+0.18), PRXL: 62.91 (-0.18), ILMN: 198.54 (+1.81), AGIO: 118.55 (+0.11), PRAH: 27.19 (+0.31), BMY: 60.04 (+0.56), ICLR: 60.01 (+0.38)
11 Best Mid-Cap Health Care Stocks Worth Targeting for 2015
at The Street - Fri Jan 02, 1:43PM CST
Which mid-cap health care companies should you target for the best returns? Click through to see which stocks are top-rated.
ACHC: 63.20 (-0.45), SIRO: 91.06 (+0.18), WST: 51.35 (+0.57), USPH: 41.08 (+0.07), ATRI: 332.77 (-2.85), STE: 65.50 (-0.35), GB: 50.86 (+0.20), TFX: 112.07 (+0.47), ICLR: 60.01 (+0.38), CMN: 44.28 (+1.09), UTMD: 58.02 (-0.40)
Healthways-TAL to Improve Well-Being Solutions in Australia - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 5:25PM CST
Healthways Inc. (HWAY) recently entered into a partnership with Australia's specialty life insurer TAL to jointly provide improvement solutions for the latter's members.
EVHC: 36.20 (-0.09), HWAY: 21.32 (+0.01), CRL: 73.61 (-0.33), ICLR: 60.01 (+0.38)
Air Methods: A Strong Sell on Weak Q3 & Estimate Revision - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 12:30PM CST
On Dec 17, 2014, Zacks Investment Research downgraded medical services provider Air Methods Corp (AIRM) to a Zacks Rank #5 (Strong Sell).
AIRM: 45.33 (+0.24), EVHC: 36.20 (-0.09), HQY: 20.02 (+0.04), ICLR: 60.01 (+0.38)
ICON (ICLR) Now a Strong Buy: Should It Be in Your Portfolio? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 5:00PM CST
ICON has been witnessing rising earnings estimates on the back of a new FDA project and an increased guidance for fiscal 2014.
EVHC: 36.20 (-0.09), HQY: 20.02 (+0.04), CRL: 73.61 (-0.33), ICLR: 60.01 (+0.38)
Cancer Genetics (CGIX) Looks Good: Stock Rises 8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 8:25AM CST
Cancer Genetics (CGIX) was a big mover last session, with shares rising just over 8% on the day.
Q: 63.31 (+0.06), CRL: 73.61 (-0.33), ICLR: 60.01 (+0.38), CGIX: 7.07 (unch)
BioTelemetry (BEAT) Catches Eye: Stock Jumps 5.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 28, 7:30AM CST
BioTelemetry, Inc. (BEAT) was a big mover last session, as the company saw its shares rise roughly 6% on the day.
EVHC: 36.20 (-0.09), BEAT: 10.36 (+0.20), CRL: 73.61 (-0.33), ICLR: 60.01 (+0.38)
Will Higher Expenses Hurt Intrexon (XON) Earnings in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 9:50AM CST
Intrexon Corporation (XON) is set to report third-quarter 2014 results on Nov 13.
MNK: 115.01 (+2.51), BEAT: 10.36 (+0.20), XON: 39.30 (+1.05), ICLR: 60.01 (+0.38)
Intrexon (XON) Looks Good: Stock Moves 11% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 8:46AM CST
Intrexon (XON) was a big mover last session, with shares rising almost 11% on the day.
BEAT: 10.36 (+0.20), XON: 39.30 (+1.05), CRL: 73.61 (-0.33), ICLR: 60.01 (+0.38)
Regulatory Affairs Outsourcing Market - Global Industry Analysis 2014 - 2020
M2 - Tue Nov 11, 9:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/8t6h79/regulatory) has announced the addition of the "Regulatory Affairs Outsourcing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020" report to their offering. The global regulatory affairs outsourcing market is segmented by services into regulatory affairs; clinical trial applications and product registrations; regulatory writing and publishing; regulatory consulting and legal representation; and others (post approval maintenance, reimbursement consulting etc.). Regulatory writing and publishing services accounted for the largest share of more than 40% of the overall regulatory affairs outsourcing market in 2013 and is expected to maintain its lead during the forecast period through 2014 to 2020. Factors that have contributed towards the large market size of the regulatory writing and publishing services are increasing need for user/reviewer friendly and complete drug application submissions, and sound knowledge for drug development services. Additionally, a well-written clinical study report (CSR) can help in adding a lot of value in the final production of clinical trial documentation, thereby complying with stringent regulatory requirements of the drug development process. The regulatory consulting and legal representation services segment is also estimated to grow at an approximate CAGR of above 14%. The major driving factors for the rapid growth of this segment are growing demand of drug manufacturing companies for product safety and efficacy evaluations. Furthermore, the need of various pharmaceutical companies to minimize business impacts such as product recalls and loss of sales, and ensure global environmental compliance would also propel the growth of the regulatory consulting and legal representation services segment. Currently, the regulatory affairs outsourcing market is fragmented due to the involvement of several established and emerging contract research organizations. Some of the major players operating in the global regulatory affairs outsourcing market are Charles River Laboratories International, Inc., Covance Group Ltd., Parexel International Corporation, WuXi AppTec, Quintiles Transnational Holdings, Inc., Medpace, Inc., Promedica International, Clinilabs, Inc., Accell Clinical Research, LLC, Criterium, Inc., ICON plc and Pharmaceutical Product Development. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Regulatory Affairs Outsourcing Market Overview Chapter 4 Global Regulatory Affairs Outsourcing Market, by Services Chapter 5 Global Regulatory Affairs Outsourcing Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles - Accell Clinical Research, LLC - Charles River Laboratories International, Inc. - Clinilabs, Inc. - Covance, Inc. - Criterium, Inc. - ICON plc - Medpace, Inc. - PAREXEL International Corporation - PRA International, Inc. - Pharmaceutical Product Development, LLC - Promedica International - Quintiles Transnational Corporation - WuXi AppTec For more information visit http://www.researchandmarkets.com/research/8t6h79/regulatory
PRXL: 62.91 (-0.18), CRL: 73.61 (-0.33), ICLR: 60.01 (+0.38), CVD: 107.08 (+0.05)
Should You Get Rid of Air Methods (AIRM) Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 7:42AM CST
Air Methods has witnessed a significant price decline in the past four weeks and negative earnings estimate revisions for the current quarter and the current year, making it time for investors to sell it off
AIRM: 45.33 (+0.24), Q: 63.31 (+0.06), BEAT: 10.36 (+0.20), ICLR: 60.01 (+0.38)
Air Methods (AIRM) Crumbles: Stock Falls by 7.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:39AM CST
Shares of Air Methods (AIRM) fell by nearly 8% on the day. This continues the recent trend for AIRM, as the stock is now down over 23% since Oct 10. This suggests there may be more trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent slump will continue.
BGMD: 0.88 (unch), AIRM: 45.33 (+0.24), BEAT: 10.36 (+0.20), ICLR: 60.01 (+0.38)
MedAssets Beats on Q3 Earnings, Revenues; Both Rise Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 9:55AM CST
MedAssets, Inc. (MDAS) reported adjusted earnings per share (EPS) of 29 cents in the third quarter of 2014, beating the Zacks Consensus Estimate by couple of cents.
BGMD: 0.88 (unch), BEAT: 10.36 (+0.20), MDAS: 19.81 (+0.18), ICLR: 60.01 (+0.38)
PAREXEL International Beats Q1 Earnings, Misses Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 9:48AM CST
PAREXEL International (PRXL) reported adjusted earnings per share of 65 cents in the first quarter of fiscal 2015, which beat both the Zacks Consensus Estimate of 58 cents and the year-ago earnings of 45 cents.
BGMD: 0.88 (unch), PRXL: 62.91 (-0.18), BEAT: 10.36 (+0.20), ICLR: 60.01 (+0.38)
ICON Selected by the FDA to Develop New Patient-Reported Outcome Measure for Hospital-Acquired Bacterial Pneumonia Trials
Business Wire - Thu Nov 06, 5:11AM CST
ICON plc, (NASDAQ: ICLR) a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been awarded a project by the US Food & Drug Administration (FDA) to develop an industry-standard Patient Reported Outcome (PRO) measure that can be used in anti-bacterial drug development trials for hospital-acquired bacterial pneumonia (HABP).
ICLR: 60.01 (+0.38)
Covance to be Acquired by LabCorp, Shares Surge 25.9% - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 4:15PM CST
Drug-development company Covance Inc.'s (CVD) share price jumped 25.9% to close at $110.57 yesterday
BEAT: 10.36 (+0.20), LH: 116.90 (+0.06), ICLR: 60.01 (+0.38), CVD: 107.08 (+0.05)
